Close Menu

NEW YORK — Canopy Biosciences said today it has acquired biopharma services firm Core Diagnostics.

With the purchase, St. Louis, Missouri-based Canopy acquires Core's CLIA facility, from which it will provide its multi-omic immune profiling services.

Core also offers NanoString transcriptional profiling and histopathology services including immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.